Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (625)	2/12/1999 1:10:00 PM
From: Invest2Ride	Read Replies (2) \| Respond to of 2001

I meant contrast publications, not returns. LIPO and GLIA are at different stages regarding trials vs. sales. I respect LIPO's diligence at having their collaborating scientists publish in well-respected, peer-reviewed journals. In the long run, that means their products will have an easier time getting market penetration. I submitted that message to inform investors of the physician perspective. Journalists only cover meetings, they rarely delve into the underlying evaluation of the quality of results presented. Meeting abstracts have little oversight and verification of results. Presenters can claim anything they want at a meeting. Until the findings are repeated and/or accepted into peer-reviewed publication, the general surgeon population will resist changing from whatever they're using now (even if it's NOTHING!) I have great respect for the potential of GLIA's products. As both a molecular/clinical scientist and an investor, I'm expressing a concern that relates to market penetration, not quality of product.